The purpose of this study is to determine the optimal dose and regimen of HM11260C, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.

Phase 2 study

1. Inclusion Criteria:

   • Age: 18 years to 65 years
   • Genders: male and female
   • healthy obese population
   • non-diabetes
   • stable body weight for at least 3 months prior to screening

2. Exclusion Criteria

   • Pregnant or nursing (lactating) women
   • Drug-induced obesity
   • Diabetes mellitus (type 1, 2, and other)
   • Previous surgical treatment for obesity
   • Any known history of severe gastrointestinal (GI) disease or intolerance
   • Known history of pancreatitis with presence of raised serum amylase and lipase
   • History of suicide attempts or recent history (within 2 years prior to screening) of major depression, anxiety, or other psychiatric disease requiring treatment with prescription medication including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitor s (SNRIs), antipsychotics, and lithium.